Reaction

Bone Cancer reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,313 reports · 67 co-occurring drugs

As of the last recalculation, Bone Cancer appears in 4,313 FAERS reports alongside 67 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 18.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ribociclib	115	18.0	18.1
Ranitidine Hydrochloride	175	16.2	16.2
Ranitidine	527	14.4	14.5
Fulvestrant	69	10.2	10.2
Goserelin	28	10.1	10.1
Anastrozole Tablets	41	9.3	9.3
Octreotide Acetate	55	8.8	8.8
Leuprolide Acetate	130	8.3	8.3
Chlorhexidine Gluconate	14	7.4	7.4
Enzalutamide	87	7.3	7.3
Letrozole	89	7.1	7.1
Anastrozole	49	6.5	6.5
Letrozole Tablets	64	6.5	6.5
Everolimus	64	6.1	6.2
Alpelisib	11	6.1	6.1
Ado-Trastuzumab Emtansine	10	5.7	5.7
Bicalutamide	18	5.7	5.7
Exemestane	24	5.4	5.4
Abiraterone Acetate	44	5.2	5.2
Palbociclib	99	5.1	5.1
Hyoscyamine Sulfate	8	4.2	4.2
Cabozantinib	39	3.9	3.9
Pazopanib Hydrochloride	22	3.9	3.9
Olaparib	17	3.9	3.9
Abiraterone	11	3.9	3.9
Lanreotide Acetate	6	3.7	3.7
Zoledronic Acid	29	3.5	3.5
Osimertinib	23	3.5	3.5
Denosumab	137	3.3	3.3
Apalutamide	8	3.3	3.3
Ranolazine	7	3.2	3.2
Erythropoietin	12	2.8	2.8
Lapatinib	9	2.8	2.8
Abemaciclib	11	2.7	2.7
Thalidomide	20	2.6	2.6
Risankizumab-Rzaa	41	2.4	2.4
Acalabrutinib	6	2.4	2.4
Insulin Glulisine	5	2.4	2.4
Relugolix	11	2.3	2.3
Axitinib	9	2.2	2.2
Lenvatinib	15	2.2	2.2
Trastuzumab	31	2.2	2.2
Capecitabine	41	2.2	2.2
Vismodegib	4	2.2	2.2
Tiotropium Bromide Inhalation Spray	5	2.2	2.2
Dabrafenib	9	2.1	2.1
Pertuzumab	11	2.0	2.0
Encorafenib	4	2.0	2.0
Lutetium Lu 177 Vipivotide Tetraxetan	5	1.8	1.8
Venetoclax	23	1.8	1.8
Trametinib	9	1.8	1.8
Darbepoetin Alfa	20	1.8	1.8
Selinexor	3	1.7	1.7
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	3	1.6	1.6
Fam-Trastuzumab Deruxtecan-Nxki	3	1.4	1.4
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	12	1.4	1.4
Patiromer	4	1.4	1.4
Budesonide, Glycopyrrolate, And Formoterol Fumarate	3	1.4	1.4
Carfilzomib	8	1.4	1.4
Ixazomib	8	1.3	1.3
Tafamidis	3	1.2	1.2
Diroximel Fumarate	3	1.2	1.2
Avapritinib	3	1.2	1.2
Pirfenidone	9	1.1	1.1
Romosozumab-Aqqg	3	1.1	1.1
Pomalidomide	20	0.9	0.9
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	4	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.